CV Sciences (CVSI) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was $3.2 million, down 11.4% year-over-year and slightly down sequentially, reflecting a challenging market and regulatory environment.

• Gross margin improved to 48.9% from 46.0% in Q1 2025, driven by lower product costs, insourcing manufacturing, and product mix optimization.

• Operating expenses declined by 13.3% year-over-year to $1.9 million, reflecting ongoing cost discipline and reductions in sales, marketing, and general administrative costs.

• Adjusted EBITDA loss narrowed to $0.1 million from $0.3 million in Q1 2025, showing progress toward profitability.

• The company is diversifying into non-cannabinoid health and wellness products, expanding internationally, and integrating recent acquisitions.

Financial highlights

• Net loss for Q1 2026 was $0.6 million, compared to $0.1 million in Q1 2025, primarily due to the absence of a one-time payroll tax reversal benefit.

• Operating loss was $0.3 million, versus operating income of $11,000 in Q1 2025 (prior year benefited from a $0.5 million payroll tax accrual reversal).

• Positive operating cash flow of $0.2 million was generated, compared to cash usage in the prior year.

• Cash at quarter-end was $0.3 million, with a working capital deficit of $0.2 million.

• Inventory reduced to $3.9 million from $4.1 million at year-end.

Outlook and guidance

• Multiple non-cannabinoid product launches and international expansion are planned for 2026 to drive organic growth and offset regulatory pressures.

• Management expects further gross margin improvement in the second half of 2026 through product mix and operational optimization.

• The company is evaluating the impact of new federal legislation restricting hemp-derived products with >0.4mg THC per container, effective November 2026.

• Operational synergies from recent acquisitions are anticipated to contribute to positive cash flow in the second half of 2026.

• The company is preparing for new healthcare channel opportunities following recent CMS and FDA regulatory developments.